Genmab A/S
Genmab A/S (GNMSF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gnmsf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Genmab A/S (GNMSF) measures how much investors pay for each dollar of the company's trailing earnings. GNMSF's current PE ratio of 18.61x is calculated by dividing its stock price of $249.45 by its TTM earnings per share of $13.36. −40.3% discount vs 5Y avg 31.2x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%43.6x
MedianQ3 · 75%96.7x
Max
At 18.61x, GNMSF's current P/E is lower than in 8% of its annual fiscal year readings over the past 13 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Genmab A/SYou GNMSF | $15.3B | 18.61x | -57.6% | $13.36 |
 Astellas Pharma Inc. ALPMF | $25.9B | 15.65x | -64.4% | $163.79 |
 Astellas Pharma Inc. ALPMY | $24.2B | 14.92x | -66.0% | $172.58 |
 bioMérieux S.A. BMXXY | $9.9B | 33.13x | -24.5% | $0.32 |
 Grifols, S.A. GIKLY | $14.2B | 18.68x | -57.5% | $0.28 |
 Innovent Biologics, Inc. IVBXF | $15.8B | 144.30x | +228.7% | $0.47 |
 Orion Oyj ORINY | $22.9B | 36.71x | -16.4% | $0.85 |
Industry Average 6 peers with valid PE | — | 43.90x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 19.58x | $16.04 | +59.0% | |
2024-12-31 FY2024 | 12.31x | $121.36 | -61.5% | |
2023-12-31 FY2023 | 31.99x | $66.64 | -10.2% | |
2022-12-31 FY2022 | 35.61x | $83.38 | -36.9% | |
2021-12-31 FY2021 | 56.46x | $45.22 | +61.7% | |
2020-12-31 FY2020 | 34.92x | $73.00 | -16.7% | |
2019-12-31 FY2019 | 41.91x | $34.40 | -3.8% | |
2018-12-31 FY2018 | 43.58x | $24.03 | -23.6% | |
2017-12-31 FY2017 | 57.01x | $18.14 | +0.4% | |
2016-12-31 FY2016 | 56.77x | $19.83 | -17.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Genmab A/S (GNMSF) measures how much investors pay for each dollar of the company's trailing earnings. GNMSF's current PE ratio of 18.61x is calculated by dividing its stock price of $249.45 by its TTM earnings per share of $13.36.
Frequently asked questions
GNMSF pe ratio · 6 questionsGNMSF's current PE ratio is 18.61x as of 2026-06-08, based on a stock price of $249.45 and TTM EPS of $13.36. Data sourced from Financial Modeling Prep via GNMSF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Genmab A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08